AMENDMENT TO TECHNOLOGY LICENSE AGREEMENT BETWEEN NICHE TECHNOLOGIES, INC. (DBA NICHE PROPERTIES) AND FAIRWAY PROPERTIES, INC. DATED MARCH 5, 2010Technology License Agreement • April 26th, 2010 • Fairway Properties, Inc. • Services-computer programming, data processing, etc.
AMENDED TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • November 12th, 2010 • GreenCell, Inc • Electronic components, nec • Florida
THIS AMENDED TECHNOLOGY LICENSE AGREEMENT (the “Agreement”) is made and entered into this 30th day of June, 2010, by and between SenCer Inc., a New York corporation (“Licensor”), and GreenCell, Incorporated, a to be formed Florida Corporation (the “Company”).
EXHIBIT 10.9 AMENDED AND RESTATED TECHNOLOGY LICENSE AGREEMENT This Amended and Restated Technology License Agreement (the "Agreement") is made and entered into as of the 19th day of May, 2005, by and between TERRA INSIGHT CORPORATION, a Delaware...Technology License Agreement • May 25th, 2005 • Compuprint Inc • Miscellaneous manufacturing industries • New York
RECITALSTechnology License Agreement • June 8th, 2006 • Photronics Inc • Semiconductors & related devices • Delaware
TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • December 28th, 2011 • Mri Interventions, Inc. • Surgical & medical instruments & apparatus • Minnesota
THIS TECHNOLOGY LICENSE AGREEMENT (this “Agreement”) is made effective as of March 19, 2008 (the “Effective Date”) and entered into by and between Surgi-Vision, Inc., a Delaware corporation (“SVI”), and Cardiac Pacemakers, Inc. (“CPI”) (individually, a “Party” and collectively, the “Parties”).
NMAP TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • April 17th, 2020 • Washington
THIS NMAP TECHNOLOGY LICENSE AGREEMENT (together with all exhibits and other attachments hereto, the "Agreement") is entered into and effective as of the last signature date set forth below, or 14 days after the first signature on the fully executed contract, whichever is earlier (“Effective Date”), by and between (“Licensee”), and Insecure.Com, LLC, a California company located at 113 Cherry St #1337, Seattle, WA 98104-2205 (“Insecure”).
TECHNOLOGY LICENSE AGREEMENT CONFIDENTIAL TREATMENT REQUESTEDTechnology License Agreement • March 2nd, 2009 • Helix BioPharma Corp • Pharmaceutical preparations • Ontario
INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND IS IDENTIFIED BY THREE ASTERISKS, AS FOLLOWS “* * *”, AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
RECITALSTechnology License Agreement • March 30th, 1998 • Spiros Development Corp Ii Inc • Pharmaceutical preparations • California
TECHNOLOGY LICENSE AGREEMENT *Confidential treatment has been requested and a complete copy of this agreement has been filed with the Commission. Redacted portions are marked throughout.Technology License Agreement • August 31st, 2009 • Neptune Technologies & Bioressources Inc. • Quebec
This TECHNOLOGY LICENSE AGREEMENT (the “Agreement”) entered into this 15th day of October, 2008 (the “Effective Date”) by and between Neptune Technologies & Bioressources Inc. (“Licensor”) and Neuro Vimer Pharm Inc. renamed NeuroBioPharm Inc. (the “Company”) (Licensor and the Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties”). Agreement reviewed the 20 February 2009.
TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • April 10th, 2013 • BioAmber Inc. • Industrial organic chemicals • Delaware
This Agreement (the “Agreement”), made and effective as of the Effective Date, by and between Celexion, LLC, a Delaware limited liability company having its principal place of business at One Memorial Drive, Suite 7, Cambridge, MA 02142 (hereinafter referred to as “Celexion” or “Licensor”) and DNP Green Technology, Inc., a Delaware corporation having its principal place of business at 1250 Rene-Levesque West, Suite 4110, Montreal, QC, Canada, H3B 4W8 (hereinafter referred to as “DNP Green” or “Licensee”).
EXHIBIT 10.19 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. Oak Technology, Confidential TECHNOLOGY LICENSE AGREEMENT THIS...Technology License Agreement • June 28th, 2002 • Tvia Inc • Semiconductors & related devices • California
SONICS, INC. RESTATED AND AMENDED TECHNOLOGY LICENSE AGREEMENT FOR TOSHIBA*Technology License Agreement • March 10th, 2008 • Sonics, Inc. • Semiconductors & related devices • California
PATENT & TECHNOLOGY LICENSE AGREEMENT [use for Exclusive Licenses to technology solely owned by Board and made solely at MDA with Patent Applications on file]Technology License Agreement • May 15th, 2012 • Texas
This Patent and Technology License Agreement (“Agreement”) is by and between The Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas, whose address is 210 West 7th Street, Austin, Texas 78701, on behalf of The University of Texas M. D. Anderson Cancer Center (“MD Anderson”), a member institution of System, and [Company name], a [jurisdiction] [corporation/LLC/etc.], with its principal place of business at _____________ (“Licensee”) (collectively, “Parties”, or singly, “Party”).
RECITALSTechnology License Agreement • August 30th, 2000 • Curon Medical Inc • Electromedical & electrotherapeutic apparatus • California
TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • April 10th, 2013 • BioAmber Inc. • Industrial organic chemicals • Delaware
This Technology License Agreement (hereinafter “Agreement”) dated February 15th, 2012 (the “Effective Date”) is by and among Sinoven Biopolymers, Inc., a corporation duly organized and existing under the laws of the State of Delaware, having its principal place of business in Malvern, Pennsylvania (hereinafter called “Sinoven”); NatureWorks LLC, a limited liability company organized and existing under the laws of the State of Delaware, having its principal place of business in Minnetonka, Minnesota (hereinafter called “NatureWorks”); AmberWorks LLC, a limited liability company duly organized and existing under the laws of the State of Delaware, having its principal place of business in Plymouth, Minnesota (hereinafter called “LLC”), and BioAmber, Inc. a corporation duly organized and existing under the laws of the State of Delaware (hereinafter called “BioAmber”).
Technology License AgreementTechnology License Agreement • July 7th, 2011 • China Ming Yang Wind Power Group LTD • Engines & turbines
In this Contract, Party B transfers the use right of technological know-how of 1.5MW wind turbine design and manufacturing technology and engineering service technology to Party A and Party A shall pay relevant charges. The following agreement is hereby concluded between and abided by the two parties through consultation on the basis of equality and truly and sufficiently expressing their will according to “Contract Law of the People’s Republic of China”.
ADDENDUM TO TECHNOLOGY LICENSE AGREEMENT by and between AF CHEMICALS LLC and LANTERN PHARMA, INC.Technology License Agreement • April 16th, 2020 • Lantern Pharma Inc. • Pharmaceutical preparations
This Addendum is attached to and forms part of the Technology License Agreement by and between Lantern Pharmaceuticals Inc., a Texas corporation (hereinafter referred to as “LANTERN”) having principal offices at 4287 Beltline Rd., Suite #270, Addison, TX 75001 and AF Chemicals, LLC, a Californian Limited Liability Company having principal offices at 5545 Coral Reef, La Jolla, CA 92037 (hereinafter referred to as “AFC”) as of February 8, 2016 (the “EFFECTIVE DATE”) (hereinafter the “LANTERN AFC ADDENDUM”). LANTERN and AFC are sometimes each individually referred to hereinafter as a “Party” and collectively referred to hereinafter as the “Parties”. To the extent that any of the terms or conditions contained in this LANTERN AFC ADDENDUM may contradict or conflict with any of the terms or conditions of the Technology License Agreement dated January 15, 2015, it is expressly understood and agreed that the terms of this LANTERN AFC ADDENDUM shall take precedence and supersede the Technology
TECHNOLOGY LICENSE AGREEMENT BY AND AMONG KAMADA LTD. AND BAXTER HEALTHCARE S.A. DATED: AUGUST 23, 2010 TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • May 15th, 2013 • Kamada LTD • Pharmaceutical preparations • New York
THIS TECHNOLOGY LICENSE AGREEMENT (this “Agreement”) is made and entered into as of 5:00 PM Eastern Daylight Time, August 23, 2010 (the “Effective Date”), by and among Kamada, Ltd., an Israeli corporation, having a principal place of business at Science Park, Kiryat Weizmann, 7 Sapir Street, P.O. Box 4081, Ness Ziona 74140, Israel (“Kamada”) and Baxter Healthcare SA (“Baxter”) a Swiss corporation having a principal place of business at Postfach, 8010, Zurich, Switzerland.
Exhibit 10.1 ------------Technology License Agreement • September 19th, 2008 • Copytele Inc • Computer peripheral equipment, nec
TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • September 21st, 2009 • Maxygen Inc • Services-commercial physical & biological research • New York
This Technology License Agreement (this “Agreement”) is entered into as of the 18th day of September, 2009 (“Effective Date”) by and between Maxygen, Inc., a Delaware corporation with its principal place of business at 515 Galveston Drive, Redwood City, California 94063 (“Maxygen”), and Perseid Therapeutics LLC, a Delaware limited liability company with its principal place of business at 515 Galveston Drive, Redwood City, California 94063 (“CPC”). Maxygen and CPC are each referred to herein by name or, individually, as a “Party” or, collectively, as the “Parties.”
TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • September 29th, 2014 • Exelis Inc. • Communications equipment, nec • Virginia
This TECHNOLOGY LICENSE AGREEMENT (this “Agreement”) dated September 25, 2014 by and among EXELIS INC., an Indiana corporation (“Exelis”), and VECTRUS, INC., an Indiana corporation (“Vectrus”, Exelis and Vectrus, each a “Party”) shall become effective as of the Distribution Date.
TECHNOLOGY LICENSE AGREEMENT BETWEENTechnology License Agreement • July 25th, 2017 • Q BioMed Inc. • Pharmaceutical preparations • Oklahoma
This Technology License Agreement (“Agreement”) is by and between the Rajiv Gandhi Center for Biotechnology, an autonomous research institute under the Govt. of India, located at Thycaud (PO), Poojappura, Thiruvananthapuram, Kerala State 695014, India (“RGCB”), the Oklahoma Medical Research Foundation, a nonprofit corporation, located at 825 NE 13th Street, Oklahoma City, OK 73104 ("OMRF") and QBiomed, Inc, a for-profit corporation, with offices at 501 Madison Ave, 14th Floor, New York, NY 10022 and its wholly-owned subsidiary, Q BioMed Cayman SEZC, a Cayman corporation (collectively, "COMPANY"). OMRF, RGCB and COMPANY shall be individually referred to as a “Party” and collectively referred to as “Parties” in this Agreement.
TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • April 5th, 2023 • GBT Technologies Inc. • Services-management consulting services • Nevada
THIS TECHNOLOGY LICENSE AGREEMENT (the “Agreement”) is made and entered into this 3 day of April, 2023, (the “Effective Date”), by and between Trend Innovations Holding, Inc., a Nevada corporation (“Licensor”), and, GBT Technologies, Inc., a Nevada corporation (“GBT”), GBT Tokenize Corp, a Nevada limited liability company and a 50% owned subsidiary of GBT (“Subsidiary” and together with GBT, the “Company”).
This Technology License Agreement (“Agreement”) is made and entered into the day of July 2001 (“Effective Date”) BETWEEN ARM LIMITED whose registered office is situated at 110 Fulbourn Road, Cambridge CB1 9NJ, England (“ARM”) andTechnology License Agreement • March 15th, 2010 • Magnachip Semiconductor LLC • Semiconductors & related devices • London
HYNIX SEMICONDUCTOR INC. a company organised and existing under the laws of the Republic of Korea and whose principal place of business is situated at San 136-1, Ami-ri, Bubal-eub, Ichon-si, Kyoungki-do, Republic of Korea (“LICENSEE”).
TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • November 23rd, 2009 • Neptune Technologies & Bioressources Inc. • Pharmaceutical preparations • Quebec
This TECHNOLOGY LICENSE AGREEMENT (the “Agreement”) entered into this 7th day of August, 2008 (the “Effective Date”) by and between Neptune Technologies & Bioressources Inc. (“Licensor”) and Acasti Pharma Inc. (the “Company”) (Licensor and the Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties”). Agreement reviewed the 20 February 2009.
Technology License Agreement BetweenTechnology License Agreement • July 21st, 2015 • ADESTO TECHNOLOGIES Corp • Semiconductors & related devices • Arizona
THIS IS A TECHNOLOGY LICENSE AGREEMENT (“Agreement”), entered into this 15th day of January, 2007 (the “Effective Date”), by and between AXON TECHNOLOGIES CORPORATION (“Axon”), a Delaware corporation having its principal place of business at 7702 E. Doubletree Ranch Road, Suite 300, Scottsdale, AZ 85258, and ADESTO TECHNOLOGIES CORPORATION INC. (“Adesto”), a California corporation having its principal place of business at 440 N. Wolfe Road, Sunnyvale, CA 94058.
Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. ATHEROS TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • March 9th, 2010 • Meru Networks Inc • Computer communications equipment • California
This Technology License Agreement (“License” or “Agreement”) is made and entered into as of the Effective Date by and between Atheros Communications, Inc. (“Atheros” or “we” or “us”), and the licensee identified above (“Licensee” or “you”). The parties, intending to be legally bound, agree as follows:
FORM OF SECOND AMENDMENT TO THE AMENDED AND RESTATED TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • March 30th, 2021 • Synaptogenix, Inc. • Pharmaceutical preparations
This Second Amendment to the Amended and Restated Technology License and Services Agreement, dated as of November 29, 2018 (“Execution Date”), is made by and between Neurotrope Bioscience, a Delaware corporation (“Neurotrope”), on the one hand, and Cognitive Research Enterprises Inc., a not-for-profit institution organized and existing under the laws of the State of West Virginia (“CRE” FKA the Blanchette Rockefeller Neurosciences Institute, Inc.), and NRV II, LLC, a limited liability company organized under and existing under the laws of the State of Delaware (“NRV II”), on the other hand. Each of Neurotrope, CRE and NRV II may be referred to as a “Party” and collectively as “Parties” in this Amendment as the case may be.
PATENT & TECHNOLOGY LICENSE AGREEMENT AGT. NO. L2549-LogicBioTechnology License Agreement • October 9th, 2018 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Texas
This Patent and Technology License Agreement (“Agreement”) is between The Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas whose address is 201 West 7th Street, Austin, Texas 78701 on behalf of The University of Texas Southwestern Medical Center (“UT Southwestern”), a component institution of System, whose address is 5323 Harry Hines Boulevard, Dallas, Texas 75390-9094 (“Licensor”) and LogicBio Therapeutics, Inc., a Delaware corporation, with its principal place of business at 700 Main Street, Cambridge, MA 02139 (“Licensee”) (collectively, “Parties”, or singly, “Party”).
amended and restated Technology License AgreementTechnology License Agreement • November 21st, 2011 • Cyclone Power Technologies Inc • Motors & generators
This amended and restated Technology License Agreement (“Agreement”) is entered into as of June 15, 2011, and shall fully restate that Technology License Agreement dated May 4, 2009, by and between:
FIRST AMENDMENT TO THE TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • May 28th, 2013 • Kamada LTD • Pharmaceutical preparations
This First Amendment to the Technology License Agreement dated August 23rd, 2010 by and between Baxter Healthcare SA, a Swiss corporation having a principal place of business at Postfach, 8010, Zurich, Switzerland (hereinafter “Baxter”) and Kamada Ltd., having a place of business at Science Park, Kiryat Weizmann, 7 Sapir St., Ness-Ziona, 74036, Israel (hereinafter “Kamada”) (the “Agreement”) is entered into as of this 14th day of May, 2013 (the “Effective Date”). Baxter and Kamada shall collectively be referred to as the “Parties”.
TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • November 16th, 2011 • Plures Technologies, Inc./De • Semiconductors & related devices • California
This Technology License Agreement (the “Agreement”) dated as of ___[blank]__________________, 1999 (the “Effective Date”), is entered into by and between Quantum Corporation (“Quantum”), a Delaware corporation, and Advanced MicroSensors, Inc. (“AMS”), a Delaware corporation.
AMENDED AND RESTATED TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • August 18th, 2006 • Open Energy Corp • Crude petroleum & natural gas • Nevada
Open Energy Corporation, a Nevada corporation, with offices at 514 Via de la Valle, Suite 200, Solana Beach, CA 92075 (the “Licensee,” and, collectively, with Licensor, the “Parties”),
BETWEEN SCIONA LIMITED AND GENAISSANCE PHARMACEUTICALS, INC.Technology License Agreement • February 23rd, 2004 • Genaissance Pharmaceuticals Inc • Services-commercial physical & biological research • Connecticut
THIS AGREEMENT, effective as of November 17, 2003 (the “Effective Date”), between SCIONA LIMITED, a corporation duly organized and existing under the laws of United Kingdom, and having its principal place of business at 25 Broadmarsh Business and Innovation Centre, Harts Farm Way, Havant Hampshire, PO9 1HS, United Kingdom; and GENAISSANCE PHARMACEUTICALS, INC., a corporation duly organized and existing under the laws of the State of Delaware, and having its principal place of business at Five Science Park, New Haven, Connecticut 06511.
AMENDED AND RESTATED TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • July 17th, 2013 • Medbox, Inc. • Air-cond & warm air heatg equip & comm & indl refrig equip • Florida
This Amended and Restated Technology License Agreement (the "Agreement") is entered into as of February 26, 2013 (the "Effective Date"), by and between Bio-Tech Medical Software, Inc., a Florida corporation with an address of 2805 E. Oakland Park Blvd., Suite 250, Fort Lauderdale, Florida, 33306 (“Licensor”) and Medbox, Inc., a Nevada corporation with an address at 8439 W. Sunset Blvd., West Hollywood, California, 90069, (“Licensee”). Licensor and Licensee are sometimes referred to herein collectively, as the “Parties” and individually, as a “Party.”
